Vertex Pharmaceuticals Incorporated $VRTX
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS24
PHASE 3 / 2-318
RECRUITING7
READOUTS ≤12 MONTHS11
READOUT SLIPPED >6 MO48%
Delay Index: of 21 active trials registered more than a year ago, 10 have moved their primary completion (readout) date by more than 6 months since first registration (median +2.1 months). See all sponsors →
Open Vertex Pharmaceuticals Incorporated on the live radar map → 📅 $VRTX readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Biological/Vaccine NCT06832410 |
P3 | Recruiting | Type 1 Diabetes; Kidney Transplant | 10 | 2026-09-17 |
| VX-121/TEZ/D-IVA NCT05444257 |
P3 | Active, not recruiting | Cystic Fibrosis | 822 | 2026-10-30 (+13 mo) |
| Suzetrigine NCT06696443 |
P3 | Active, not recruiting | Diabetic Peripheral Neuropathic Pain | 455 | 2027-01-25 |
| Galileo NCT06185764 |
P1/2 | Active, not recruiting | Myotonic Dystrophy Type 1 (DM1) | 47 | 2027-02-02 (+2 mo) |
| VX-264 NCT05791201 |
P1/2 | Active, not recruiting | Type 1 Diabetes | 7 | 2027-03-12 (+10 mo) |
| VX-993 NCT06619860 |
P2 | Recruiting | Diabetic Peripheral Neuropathic Pain | 300 | 2027-03-25 (+12 mo) |
| ELX/TEZ/IVA NCT05331183 |
P3 | Active, not recruiting | Cystic Fibrosis | 297 | 2027-04-06 (+25 mo) |
| Suzetrigine NCT07231419 |
P3 | Recruiting | Diabetic Peripheral Neuropathic Pain | 734 | 2027-04-06 |
| Suzetrigine NCT06628908 |
P3 | Recruiting | Diabetic Peripheral Neuropathic Pain | 1100 | 2027-05-31 |
| CTX001 NCT05329649 |
P3 | Active, not recruiting | Sickle Cell Disease; Hydroxyurea Failure | 13 | 2027-06-06 (+13 mo) |
| CTX001 NCT05477563 |
P3 | Recruiting | Beta-Thalassemia; Thalassemia | 26 | 2027-06-09 (+28 mo) |
| AGLOW NCT07161037 |
P2 | Active, not recruiting | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | 26 | 2027-07-22 |
| ELX/TEZ/IVA NCT06460506 |
P3 | Active, not recruiting | Cystic Fibrosis | 50 | 2027-09-30 |
| CTX001 NCT05356195 |
P3 | Active, not recruiting | Beta-Thalassemia; Thalassemia | 16 | 2027-11-14 (+18 mo) |
| Povetacicept NCT07890909 |
P3 | Not yet recruiting | Immunoglobulin A Nephropathy | 40 | 2027-12-12 |
| VX-880 NCT04786262 |
P3 | Recruiting | Diabetes Mellitus, Type 1; Impaired Hypoglycemic Awareness | 57 | 2027-12-31 (+48 mo) |
| AMPLITUDE NCT05312879 |
P2/3 | Active, not recruiting | Proteinuric Kidney Disease | 522 | 2028-06-02 (+25 mo) |
| OLYMPUS NCT07204275 |
P2/3 | Recruiting | Primary Membranous Nephropathy | 176 | 2028-12-29 |
| VX-670 NCT06926621 |
P2 | Enrolling by invitation | Myotonic Dystrophy Type 1 (DM1) | 44 | 2029-01-30 (+6 mo) |
| ETNA NCT07501702 |
P2 | Active, not recruiting | Myasthenia Gravis, Generalized | 34 | 2029-03-02 |
| VNZ/TEZ/D-IVA NCT05844449 |
P3 | Enrolling by invitation | Cystic Fibrosis | 174 | 2029-07-30 (-14 mo) |
| Povetacicept NCT07807995 |
P3 | Enrolling by invitation | Immunoglobulin A Nephropathy | 605 | 2029-12-28 |
| VX-121/TEZ/D-IVA NCT05422222 |
P3 | Active, not recruiting | Cystic Fibrosis | 210 | 2030-06-30 |
| CTX001 NCT04208529 |
P3 | Enrolling by invitation | Beta-Thalassemia; Thalassemia | 160 | 2039-09-30 |